The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Nanoparticle‐induced platelet aggregation and vascular thrombosis
Open accessAbstract
Ever increasing use of engineered carbon nanoparticles in nanopharmacology for selective imaging, sensor or drug delivery systems has increased the potential for blood platelet–nanoparticle interactions. We studied the effects of engineered and combustion‐derived carbon nanoparticles on human platelet aggregation in vitro and rat vascular thrombosis in vivo. Multiplewall (MWNT), singlewall (SWNT) nanotubes, C60 fullerenes (C60CS) and mixed carbon nanoparticles (MCN) (0.2–300 μ g ml−1) were investigated. Nanoparticles were compared with standard urban particulate matter (SRM1648, average size 1.4 μ m). Platelet function was studied using lumi aggregometry, phase‐contrast, immunofluorescence and transmission electron microscopy, flow cytometry, zymography and pharmacological inhibitors of platelet aggregation. Vascular thrombosis was induced by ferric chloride and the rate of thrombosis was measured, in the presence of carbon particles, with an ultrasonic flow probe. Carbon particles, except C60CS, stimulated platelet aggregation (MCNSWNT>MWNT>SRM1648) and accelerated the rate of vascular thrombosis in rat carotid arteries with a similar rank order of efficacy. All particles resulted in upregulation of GPIIb/IIIa in platelets. In contrast, particles differentially affected the release of platelet granules, as well as the activity of thromboxane‐, ADP, matrix metalloproteinase‐ and protein kinase C‐dependent pathways of aggregation. Furthermore, particle‐induced aggregation was inhibited by prostacyclin and S‐nitroso‐glutathione, but not by aspirin. Thus, some carbon nanoparticles and microparticles have the ability to activate platelets and enhance vascular thrombosis. These observations are of importance for the pharmacological use of carbon nanoparticles and pathology of urban particulate matter. British Journal of Pharmacology (2005) 146, 882–893. doi:10.1038/sj.bjp.0706386
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotubular Highways for Intercellular Organelle Transport
Rustom, A., Saffrich, R., Markovic, I., Walther, P., & Gerdes, H.-H. (2004) · Science · doi:10.1126/science.1093133 · Cited by 2,038
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Passage of inhaled particles into the blood circulation in humans
Nemmar, A., Hoet, P. H. M., Vanquickenborne, B., Dinsdale, D., Thomeer, M., Hoylaerts, M. F., Vanbilloen, H., Mortelmans, L., & Nemery, B. (2002) · Circulation · doi:10.1161/hc0402.104118 · Cited by 1,719
Winter, P. M., Morawski, A. M., Caruthers, S. D., Fuhrhop, R. W., Zhang, H., Williams, T. A., Allen, J. S., Lacy, E. K., Robertson, J. D., Lanza, G. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000093185.16083.95 · Cited by 696
Cited by
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Sharifi, S., Behzadi, S., Laurent, S., Laird Forrest, M., Stroeve, P., & Mahmoudi, M. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15188f · Cited by 1,460
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Nanotechnology Safety Concerns Revisited
Stern, S. T., & McNeil, S. E. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfm169 · Cited by 560
Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge
Stone, V., Miller, M. R., Clift, M. J. D., Elder, A., Mills, N. L., Møller, P., Schins, R. P. F., Vogel, U., Kreyling, W. G., Alstrup Jensen, K., et al. (2017) · Environmental Health Perspectives · doi:10.1289/ehp424 · Cited by 370
Fourches, D., Pu, D., & Tropsha, A. (2011) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620711794728743 · Cited by 92
Mishra, A., Singh, S. K., Dash, D., Aswal, V. K., Maiti, B., Misra, M., & Maiti, P. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.12.035 · Cited by 79
CNT Induced β-Phase in Polylactide: Unique Crystallization, Biodegradation, and Biocompatibility
Singh, N. K., Singh, S. K., Dash, D., Gonugunta, P., Misra, M., & Maiti, P. (2013) · The Journal of Physical Chemistry C · doi:10.1021/jp4009042 · Cited by 68
Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer
Wang, Y., Liu, P., Duan, Y., Yin, X., Wang, Q., Liu, X., Wang, X., Zhou, J., Wang, W., Qiu, L., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.062 · Cited by 56
Nanostructure controlled anti-cancer drug delivery using poly(ε-caprolactone) based nanohybrids
Singh, N. K., Singh, S. K., Dash, D., Das Purkayastha, B. P., Roy, J. K., & Maiti, P. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm32340k · Cited by 49
The Significance and Insignificance of Carbon Nanotube-Induced Inflammation
Boyles, M., Stoehr, L., Schlinkert, P., Himly, M., & Duschl, A. (2014) · Fibers · doi:10.3390/fib2010045 · Cited by 22
Metadata
- Authors
- Radomski, A., Jurasz, P., Alonso‐Escolano, D., Drews, M., Morandi, M., Malinski, T., & Radomski, M. W.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 146
- Issue
- 6
- Pages
- 882-893
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2128858080
- Cited by
- 636
- References
- 4
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
